A 55-year-old patient with hypertension, chronic obstructive pulmonary disease (COPD), and liver cirrhosis is admitted. What is the nurse's priority action?

Metformin should be held due to chronic kidney disease (CKD) stage 3, indicating kidney impairment risk for lactic acidosis. Other options address glucose or fluid but ignore this immediate safety concern.

Understanding the Clinical Scenario
This patient presents with a complex medical history—hypertension, COPD, and liver cirrhosis—and is now exhibiting signs of acute decompensation. The priority action must address the most immediate threat to life. The patient reports worsening fatigue and orthopnea (difficulty breathing when lying flat), which, combined with the assessment findings of BP 150/90 mmHg, HR 95 bpm, RR 24/min, O2 sat 88% on room air, and 3+ pitting edema, points toward significant fluid overload and respiratory compromise.

Analyzing the Options and Identifying the Priority
The question asks for the nurse's priority action. Using the nursing process, the first step is always assessment, but when a critical finding is identified, the priority action often involves immediate safety measures, including holding a potentially harmful medication and notifying the provider.

* Option 1: Administering prescribed metformin is inappropriate. The patient's primary issue is not hyperglycemia but acute respiratory distress related to fluid overload. Furthermore, metformin use requires careful consideration of kidney and liver function.
* Option 3: Increasing the furosemide dose is outside the nurse's scope of practice without a specific provider order. A nurse cannot independently adjust medication dosages.
* Option 4: Encouraging increased fluid intake is contraindicated. This patient has clear signs of fluid volume excess (3+ pitting edema, orthopnea), and additional fluid would worsen their respiratory status.
* Option 2: Holding metformin and notifying the healthcare provider is the correct priority action. This is a safety-driven decision based on the patient's acute condition and the known risks of metformin in the context of potential lactic acidosis.

The Critical Rationale: Metformin and Lactic Acidosis Risk
The core of this question lies in recognizing a life-threatening contraindication. Metformin is renally cleared, and its accumulation in the body can lead to a rare but devastating complication: metformin-associated lactic acidosis (MALA). The patient’s presentation of acute respiratory distress (tachypnea, low O2 saturation) with a background of liver cirrhosis and fluid overload creates a perfect storm for this condition.

The clinical practice guidelines for managing hyperglycemia in adults with type 2 diabetes and chronic kidney disease explicitly highlight that metformin use must be carefully evaluated when a patient's clinical status changes ^[2]. While the guidelines focus on CKD, the underlying principle applies here: conditions that predispose a patient to acute kidney injury (AKI) or tissue hypoxia increase the risk of MALA. This patient’s severe fluid overload can lead to renal hypoperfusion and prerenal AKI, impairing metformin excretion. Simultaneously, the severe respiratory distress from pulmonary edema and underlying COPD causes tissue hypoxia. The combination of impaired drug clearance and increased anaerobic metabolism creates a high-risk state for lactic acidosis, the accumulation of lactate in the body, which is often fatal.

Furthermore, the patient has liver cirrhosis. The liver is the primary organ for clearing lactate from the blood through gluconeogenesis. A cirrhotic liver has a diminished capacity to metabolize lactate, which means any increase in lactate production or decrease in clearance can rapidly lead to a severe, uncompensated metabolic acidosis. The development of hepatocellular carcinoma (HCC) is a known risk in patients with chronic liver disease, and monitoring tools like the FIB-4 score are used to track fibrosis progression, which can eventually lead to cirrhosis and HCC ^[4]. While the provided abstract on FIB-4 does not directly discuss MALA, it underscores the progressive nature of liver disease and the importance of recognizing when a patient with cirrhosis is at risk for decompensation. A patient with established cirrhosis already has a compromised physiological reserve, making them exceptionally vulnerable to any new insult, such as lactic acidosis from metformin.

The nurse’s priority is to recognize that the patient’s acute presentation—tachypnea with hypoxia in the setting of fluid overload and liver disease—could be an early sign of or a precipitating factor for MALA. The safest immediate action is to hold the metformin to prevent further accumulation and to promptly notify the healthcare provider for further evaluation, which would likely include assessing renal function, serum lactate, and acid-base status, and providing respiratory support.